Hyderabad-based biopharmaceutical company Suven Life Sciences Limited has completed the phase-I single ascending dose study of Suvn-502 in healthy male subjects. Suvn-502 is intended for the symptomatic treatment of Alzheimer’s disease and other disorders of memory and cognition like attention deficient hyperactivity, Parkinson and Schizophrenia.
The study was conducted at Basel in Switzerland under a clinical trial application (CTA) approved by SwissMedic, the regulatory authority of Switzerland for therapeutic products, the company stated in a press release.
"We are very pleased with the results of phase-1 single ascending study with Suvn-502 in Switzerland. Suvn-502 is the first NCE (new chemical entity) of Suven to enter the clinic from a pipeline of six NCEs. The CNS ( central nervous system) market and especially the cognition is amongst the largest, about $20 billion potential market opportunity globally and this novel target presents an excellent opportunity." Venkat Jasti, Suven Life chief executive officer, said.
